Skip to content

Evaluating the role of serum procalcitonin and c-reactive protein as a marker for serious infection in young children

To assess the role of Procalcitonin and C- Reactive Protein Test in neonates and children less than 36 months of age as a marker for Serious Bacterial Infections

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2012/05/002633
Enrollment
40
Registered
2012-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- suspected serious infections

Interventions

None listed

Sponsors

MAX SUPER SPECIALITY HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: INCLUSION CRITERIA 1.Neonates admitted in NICU with possibility of Serious Bacterial Infections. 2.Children less than 36 months of age who are admitted in Max Super Speciality Hospital with fever and there is suspicion of bacterial infection in their history or physical examination. 3.Parents or legal authorized representative (LAR) who voluntarily consents to participate in the Study

Exclusion criteria

Exclusion criteria: 1. Neonates with birth asphyxia, aspiration syndromes, lab findings suggestive of inborn errors of metabolism and congenital anomalies. 2. Children with known immunodeficiencies

Design outcomes

Primary

MeasureTime frame
To validate the Procalcitonin and CRP as a biomarker for serious bacterial infections in infants and young children less than 36 months of age.Timepoint: To validate the Procalcitonin and CRP as a biomarker for serious bacterial infections in infants and young children less than 36 months of age.

Secondary

MeasureTime frame
NoneTimepoint: None

Countries

India

Contacts

Public ContactDR SUMIL GUPTA

MAX SUPER SPECIALITY HOSPITAL

sisir.paul@maxhealthcare.com9811055154

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026